Actuate Therapeutics, Inc. Common stock (ACTU) Stock Price
ACTUStock
$1.58−85.29%52W
Market Cap$37.94M
P/E—
PEG Ratio—
Div yield—
Beta1.40
ACTU Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-82.30%
Price vs S&P 500 (4W)12.99%
VGM Score23.72
ACTU Earnings Surprise History
Q2 25-0.30est. -0.32
Q3 25-0.25est. -0.28
Q4 25-0.18est. -0.24
Q1 26-0.24est. -0.21
Q2 26-0.20est. -0.20
ACTU Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACTUActuate Therapeutics, Inc. Common stock | — | — | D | $1.58 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies targeting GSK-3, a key regulator of tumor cell survival and growth. The company's lead candidate, elraglusib, is designed to inhibit GSK-3B and disrupt oncogenic signaling pathways in difficult-to-treat cancers. Actuate is pursuing a novel mechanism of action to address cancers with limited therapeutic options.